Cargando…

In vitro evaluation of the anti-pathogenic activity of Okoubaka aubrevillei on the human gastrointestinal tract

Background   Okoubaka aubrevillei is used in traditional West African medicine and in homeopathy for treatment and prevention of several gastrointestinal problems. The aim of this in vitro study was to evaluate the effect of repeated doses of two Okoubaka products (10 % ethanolic tincture, mother ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchheim-Schmidt, Susann, Peters, Uwe, Duysburgh, Cindy, Van den Abbeele, Pieter, Marzorati, Massimo, Keller, Thomas, Martin, David, Klement, Petra, Baumgartner, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516495/
https://www.ncbi.nlm.nih.gov/pubmed/33979845
http://dx.doi.org/10.1055/a-1404-3344
_version_ 1784583816175681536
author Buchheim-Schmidt, Susann
Peters, Uwe
Duysburgh, Cindy
Van den Abbeele, Pieter
Marzorati, Massimo
Keller, Thomas
Martin, David
Klement, Petra
Baumgartner, Stephan
author_facet Buchheim-Schmidt, Susann
Peters, Uwe
Duysburgh, Cindy
Van den Abbeele, Pieter
Marzorati, Massimo
Keller, Thomas
Martin, David
Klement, Petra
Baumgartner, Stephan
author_sort Buchheim-Schmidt, Susann
collection PubMed
description Background   Okoubaka aubrevillei is used in traditional West African medicine and in homeopathy for treatment and prevention of several gastrointestinal problems. The aim of this in vitro study was to evaluate the effect of repeated doses of two Okoubaka products (10 % ethanolic tincture, mother tincture (MT); 3 (rd) decimal potency, 3X) on the microbial activity of physiological human colon microbiota using a Simulator of the Human Intestinal Microbial Ecosystem (SHIME (®) ) and to investigate any preventive effect against infections with diarrhea-causing pathogens. Methods  Upon inoculation with fecal microbiota from a healthy donor, 4 parallel proximal colon compartments of the SHIME were treated either with Okoubaka MT, Okoubaka 3X, ethanol control or blank control for 7 days. Using the Okoubaka -adapted microbial community from SHIME, 48 h challenge tests were performed with enterotoxigenic Escherichia coli (ETEC) and Salmonella enteritidis in 4 different doses (10 (3) –10 (8) colony forming units as typical in vivo infectious doses). Pathogen concentrations, short-chain fatty acids (SCFAs) and branched SCFA production were measured in triplicate at 0, 24 and 48 h. Results  In the challenge tests, both Okoubaka products were able to restrict the colonization of ETEC and Salmonella at 3 of the 4 pathogen doses (except the highest doses), with a stronger anti-pathogenic effect for MT, which included a reduction of 2.0 log-units of ETEC (p < 0.0001) and 1.1 log-units of Salmonella (p < 0.0001). Total SCFA levels remained unaffected, but butyrate increased during the first 24 h (p < 0.0001 for ETEC), accompanied by decreased acetate production. Conclusion  We observed in vitro a systemic activating effect of Okoubaka on intestinal microbiome resistance, which resulted in an anti-pathogenic effect, especially against ETEC. We hypothesize that the mode of action in vivo is also based on systemic regulative effects.
format Online
Article
Text
id pubmed-8516495
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-85164952021-10-15 In vitro evaluation of the anti-pathogenic activity of Okoubaka aubrevillei on the human gastrointestinal tract Buchheim-Schmidt, Susann Peters, Uwe Duysburgh, Cindy Van den Abbeele, Pieter Marzorati, Massimo Keller, Thomas Martin, David Klement, Petra Baumgartner, Stephan Z Gastroenterol Background   Okoubaka aubrevillei is used in traditional West African medicine and in homeopathy for treatment and prevention of several gastrointestinal problems. The aim of this in vitro study was to evaluate the effect of repeated doses of two Okoubaka products (10 % ethanolic tincture, mother tincture (MT); 3 (rd) decimal potency, 3X) on the microbial activity of physiological human colon microbiota using a Simulator of the Human Intestinal Microbial Ecosystem (SHIME (®) ) and to investigate any preventive effect against infections with diarrhea-causing pathogens. Methods  Upon inoculation with fecal microbiota from a healthy donor, 4 parallel proximal colon compartments of the SHIME were treated either with Okoubaka MT, Okoubaka 3X, ethanol control or blank control for 7 days. Using the Okoubaka -adapted microbial community from SHIME, 48 h challenge tests were performed with enterotoxigenic Escherichia coli (ETEC) and Salmonella enteritidis in 4 different doses (10 (3) –10 (8) colony forming units as typical in vivo infectious doses). Pathogen concentrations, short-chain fatty acids (SCFAs) and branched SCFA production were measured in triplicate at 0, 24 and 48 h. Results  In the challenge tests, both Okoubaka products were able to restrict the colonization of ETEC and Salmonella at 3 of the 4 pathogen doses (except the highest doses), with a stronger anti-pathogenic effect for MT, which included a reduction of 2.0 log-units of ETEC (p < 0.0001) and 1.1 log-units of Salmonella (p < 0.0001). Total SCFA levels remained unaffected, but butyrate increased during the first 24 h (p < 0.0001 for ETEC), accompanied by decreased acetate production. Conclusion  We observed in vitro a systemic activating effect of Okoubaka on intestinal microbiome resistance, which resulted in an anti-pathogenic effect, especially against ETEC. We hypothesize that the mode of action in vivo is also based on systemic regulative effects. Georg Thieme Verlag KG 2021-05-12 /pmc/articles/PMC8516495/ /pubmed/33979845 http://dx.doi.org/10.1055/a-1404-3344 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Buchheim-Schmidt, Susann
Peters, Uwe
Duysburgh, Cindy
Van den Abbeele, Pieter
Marzorati, Massimo
Keller, Thomas
Martin, David
Klement, Petra
Baumgartner, Stephan
In vitro evaluation of the anti-pathogenic activity of Okoubaka aubrevillei on the human gastrointestinal tract
title In vitro evaluation of the anti-pathogenic activity of Okoubaka aubrevillei on the human gastrointestinal tract
title_full In vitro evaluation of the anti-pathogenic activity of Okoubaka aubrevillei on the human gastrointestinal tract
title_fullStr In vitro evaluation of the anti-pathogenic activity of Okoubaka aubrevillei on the human gastrointestinal tract
title_full_unstemmed In vitro evaluation of the anti-pathogenic activity of Okoubaka aubrevillei on the human gastrointestinal tract
title_short In vitro evaluation of the anti-pathogenic activity of Okoubaka aubrevillei on the human gastrointestinal tract
title_sort in vitro evaluation of the anti-pathogenic activity of okoubaka aubrevillei on the human gastrointestinal tract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516495/
https://www.ncbi.nlm.nih.gov/pubmed/33979845
http://dx.doi.org/10.1055/a-1404-3344
work_keys_str_mv AT buchheimschmidtsusann invitroevaluationoftheantipathogenicactivityofokoubakaaubrevilleionthehumangastrointestinaltract
AT petersuwe invitroevaluationoftheantipathogenicactivityofokoubakaaubrevilleionthehumangastrointestinaltract
AT duysburghcindy invitroevaluationoftheantipathogenicactivityofokoubakaaubrevilleionthehumangastrointestinaltract
AT vandenabbeelepieter invitroevaluationoftheantipathogenicactivityofokoubakaaubrevilleionthehumangastrointestinaltract
AT marzoratimassimo invitroevaluationoftheantipathogenicactivityofokoubakaaubrevilleionthehumangastrointestinaltract
AT kellerthomas invitroevaluationoftheantipathogenicactivityofokoubakaaubrevilleionthehumangastrointestinaltract
AT martindavid invitroevaluationoftheantipathogenicactivityofokoubakaaubrevilleionthehumangastrointestinaltract
AT klementpetra invitroevaluationoftheantipathogenicactivityofokoubakaaubrevilleionthehumangastrointestinaltract
AT baumgartnerstephan invitroevaluationoftheantipathogenicactivityofokoubakaaubrevilleionthehumangastrointestinaltract